Literature DB >> 9355755

Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting.

E M Bailyes1, B T Navé, M A Soos, S R Orr, A C Hayward, K Siddle.   

Abstract

The insulin receptor (IR) and type 1 insulin-like growth factor (IGF-I) receptor (IGFR) are both widely expressed in mammalian tissues, and are known to be capable of heteromeric assembly as insulin/IGF hybrid receptors, in addition to the classically described receptors. By selective immunoadsorption of radioligand/receptor complexes and by immunoblotting we have determined the fraction of insulin receptors and IGF receptors occurring as hybrids in different tissues. Microsomal membranes were isolated from tissue homogenates and solubilized with Triton X-100. Solubilized receptors were incubated with 125I-IGF-I, and radioligand/receptor complexes bound by IR-specific and IGFR-specific monoclonal antibodies were quantified. The fraction of IGF-I binding sites behaving as hybrids (anti-IR-bound/anti-IGFR-bound) was approx. 40% in liver and spleen, 70% in placenta, and 85-90% in skeletal muscle and heart, similar results being obtained in rabbit and human tissues. There was no correlation between the proportion of hybrids and the ratio of 125I-insulin/125I-IGF-I binding in different tissues. The fraction of 125I-insulin bound to hybrids was too low for accurate quantification, because of the relatively low affinity of hybrids for insulin. The fraction of insulin receptors present in hybrids was therefore determined by immunoblotting. Receptors in solubilized human placental microsomal membranes were precipitated with IR-specific or IGFR-specific monoclonal antibodies, and after SDS/PAGE, blots were prepared and probed with IR-specific and IGFR-specific antisera. It was found that 15% of IR and 80% of IGFR were present in hybrids. Consistent with these figures, the overall level of IR was estimated, by blotting with the respective antibodies at concentrations shown to give equal signals with equal amounts of receptor, to be 4-fold greater than IGFR. Overall it was concluded that a significant fraction of both IR and IGFR occurs as hybrids in most mammalian tissues, including those that are recognized targets of insulin and IGF action. The fraction of hybrids in different tissues was not a simple function of the relative levels of IR and IGFR, possibly because of heterogeneity of receptor expression in different cell types. However, in placenta the proportions of IR, IGFR and hybrids were consistent with a process of random assembly reflecting the molar ratio of IR and IGFR half-receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355755      PMCID: PMC1218783          DOI: 10.1042/bj3270209

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  The pattern of expression of insulin-like growth factor (IGF). IGF-I receptor and IGF binding protein (IGFBP) mRNAs in the rhesus monkey placenta suggests a paracrine mode of IGF-IGFBP interaction in placental development.

Authors:  C L Coulter; V K Han
Journal:  Placenta       Date:  1996-09       Impact factor: 3.481

2.  Early neonatal death in mice homozygous for a null allele of the insulin receptor gene.

Authors:  D Accili; J Drago; E J Lee; M D Johnson; M H Cool; P Salvatore; L D Asico; P A José; S I Taylor; H Westphal
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

3.  Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.

Authors:  A Ullrich; J R Bell; E Y Chen; R Herrera; L M Petruzzelli; T J Dull; A Gray; L Coussens; Y C Liao; M Tsubokawa
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

4.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts.

Authors:  C Sell; G Dumenil; C Deveaud; M Miura; D Coppola; T DeAngelis; R Rubin; A Efstratiadis; R Baserga
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

5.  Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signaling pathways.

Authors:  T Sasaoka; M Ishiki; T Sawa; H Ishihara; Y Takata; T Imamura; I Usui; J M Olefsky; M Kobayashi
Journal:  Endocrinology       Date:  1996-10       Impact factor: 4.736

6.  Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors.

Authors:  A L Frattali; J E Pessin
Journal:  J Biol Chem       Date:  1993-04-05       Impact factor: 5.157

7.  A functional assessment of insulin/insulin-like growth factor-I hybrid receptors.

Authors:  B L Seely; D R Reichart; Y Takata; C Yip; J M Olefsky
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

8.  A developmentally regulated form of insulin-like growth factor receptor beta-subunit in C2 myoblasts exhibiting altered requirements for differentiation.

Authors:  B Barenton; A Domeyne; V Garandel; R S Garofalo
Journal:  Endocrinology       Date:  1993-08       Impact factor: 4.736

9.  Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification.

Authors:  J Kasuya; I B Paz; B A Maddux; I D Goldfine; S A Hefta; Y Fujita-Yamaguchi
Journal:  Biochemistry       Date:  1993-12-14       Impact factor: 3.162

10.  Insulin receptors in syncytiotrophoblast and fetal endothelium of human placenta. Immunohistochemical evidence for developmental changes in distribution pattern.

Authors:  G Desoye; M Hartmann; A Blaschitz; G Dohr; T Hahn; G Kohnen; P Kaufmann
Journal:  Histochemistry       Date:  1994-04
View more
  87 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Proinsulin: much more than a hormone precursor in development.

Authors:  Catalina Hernández-Sánchez; Oscar Bártulos; Flora de Pablo
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

3.  Expression and function of insulin/insulin-like growth factor I hybrid receptors during differentiation of 3T3-L1 preadipocytes.

Authors:  D Modan-Moses; M Janicot; J C McLenithan; M D Lane; S J Casella
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

4.  Unexpected systemic phenotypes result from focal combined deficiencies of forebrain insulin receptor/IGF-1 receptor signaling.

Authors:  Sam Gandy; Derek M Huffman
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-11       Impact factor: 11.205

5.  Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China.

Authors:  Yanli Shao; Shijie Cheng; Jianqing Hou; Ying Zuo; Wei Zheng; Min Xia; Nan Mu
Journal:  Tumour Biol       Date:  2015-10-29

Review 6.  The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research.

Authors:  Sofiya Milman; Derek M Huffman; Nir Barzilai
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

Review 7.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 8.  IGF-1, oxidative stress and atheroprotection.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  Trends Endocrinol Metab       Date:  2010-01-12       Impact factor: 12.015

Review 9.  Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease.

Authors:  Maria Laura Giuffrida; Flora Tomasello; Filippo Caraci; Santina Chiechio; Ferdinando Nicoletti; Agata Copani
Journal:  Mol Neurobiol       Date:  2012-08-12       Impact factor: 5.590

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.